摘要
目的探讨金英胶囊联合盐酸莫西沙星片治疗慢性盆腔炎的临床疗效。方法选取2016年6月—2018年6月在新野县人民医院治疗的106例慢性盆腔炎患者作为研究对象,根据用药的差别将患者分为对照组(53例)和治疗组(53例)。对照组口服盐酸莫西沙星片,1片/次,1次/d;治疗组在对照组治疗的基础上口服金英胶囊,2.0g/次,3次/d。两组均治疗4周。观察两组患者的临床疗效,同时比较两组的临床症状改善时间、盆腔炎性包块直径、盆腔积液量和炎症指标。结果治疗后,对照组和治疗组的总有效率分别为81.13%、96.23%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组下腹腰骶疼痛、白带增多、发热、盆腔肿块消失时间均明显短于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者盆腔炎性包块直径、盆腔积液量均显著减少,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组盆腔炎性包块直径、盆腔积液量明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)、单核细胞趋化蛋白1(MCP-1)水平均显著下降,白细胞介素-4(IL-4)、白细胞介素-10(IL-10)水平均明显增高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组炎症指标水平显著优于对照组,两组比较差异具有统计学意义(P<0.05)。结论金英胶囊联合盐酸莫西沙星片治疗慢性盆腔炎可有效改善患者临床症状,降低机体炎症反应,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of Jinying Capsules combined with Moxifloxacin Hydrochloride Tablets in treatment of chronic pelvic inflammatory disease. Methods Patients(106 cases) with chronic pelvic inflammatory disease in Xinye County People's Hospital from June 2016 to June 2018 were divided into control(53 cases) and treatment(53 cases) groups according to the difference of medication. Patients in the control group were po administered with Moxifloxacin Hydrochloride Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Jinying Capsules on the basis of the control group,2.0 g/time, three times daily. Patients in two groups treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the clinical symptoms improvement time, pelvic inflammatory mass diameter, pelvic effusion volume, and inflammatory markers in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 81.13% and 96.23%,respectively, and there were differences between two groups(P < 0.05). After treatment, the times of abdomen lumbosacral pain,increased leucorrhea, fever, and pelvic mass disappearance in the treatment group were significantly shorter than those in the control group, and there were differences between two groups(P < 0.05). After treatment, pelvic inflammatory mass diameter and pelvic effusion volume in the two groups were significantly decreased, and there were differences in the same group(P < 0.05). After treatment, pelvic inflammatory mass diameter and pelvic effusion volume in the treatment group were lower than those in the control group, and there were differences between two groups(P < 0.05). After treatment, the serum IL-1β, TNF-α, and MCP-1 levels in two groups were significantly decreased, but IL-4 and IL-10 levels were significantly increased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the levels of inflammatory markers in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Jinying Capsules combined with Moxifloxacin Hydrochloride Tablets in treatment of chronic pelvic inflammatory disease can effectively improve the clinical symptoms of patients, and reduce the body inflammatory response, which has a certain clinical application value.
引文
[1]张玉珍.中医妇科学[M].第7版.北京:中国中医药出版社,2002:313-319.
[2]郑清四.盐酸莫西沙星的临床应用进展[J].华夏医学,2014,27(1):195-197.
[3]金哲,刘朝晖,黄敏.金英胶囊治疗盆腔炎性疾病的临床研究方案[J].中国中医药现代远程教育,2016,14(14):52-55.
[4]乐杰.妇产科学[M].第7版.北京:人民卫生出版社,2008:246.
[5]吴少祯,吴敏.常见疾病的诊断与疗效判定(标准)[M].北京:中国中医药出版社,1999:533-534.
[6]常建文,刘永庆.慢性盆腔炎中医药疗法体会[J].中华中医药杂志,2009(S1):75-76.
[7]费红梅.慢性盆腔炎患者血清TNF-α、IL-1β、IL-4及T淋巴细胞亚群分布变化[J].山东医药,2015,55(38):60-61.
[8]叶淑英,曾素清.盆腔炎患者外周血MCP-1测定及意义[J].中国计划生育和妇产科,2010,2(5):71-72.
[9]王莉,吕耀凤,姚丽娟.慢性盆腔炎患者促炎因子与抗炎因子的关系[J].中国妇幼保健,2012,27(33):5292-5294.
[10]张道杰,段朝霞.IL-10的研究进展[J].国外医学:免疫学分册,2003,26(1):39-41.
